文献速递浆细胞疾病造血干细胞移植与细胞治疗

帕比司他、吉西他滨、白消安和美法仑新大剂量方案用于首次或第二次挽救性自体干细胞移植治疗难治/复发或高危骨髓瘤的安全性和疗效:与同期对照队列的配对比较

Safety and efficacy of a new high-dose regimen of panobinostat, gemcitabine, busulfan, and melphalan for 1st or 2nd salvage ASCT for refractory/relapsed or high-risk myeloma: Matched-pair comparisons with concurrent control cohorts.
PubMed 文献 · Am J Hematol · 2023-12-15

本研究前瞻性评估帕比司他联合吉西他滨/白消安/美法仑(GemBuMel)方案在复发/难治或高危骨髓瘤患者自体干细胞移植(ASCT)中的安全性和疗效,并与同期接受美法仑或BuMel方案的匹配对照比较。共入组80例患者(首次ASCT组48例,第二次ASCT组32例),移植相关死亡2例(均在第二次ASCT组)。试验组首次或第二次ASCT后的无进展生存均优于匹配对照。

要点

  • 帕比司他/GemBuMel方案在首次或第二次ASCT中均可行,移植相关死亡2例(均为第二次ASCT患者)。
  • 1年无进展生存率:首次ASCT组69%,第二次ASCT组72%;1年总生存率分别为79%和84%。
  • ASCT后微小残留病阴性率在首次ASCT组从8.5%升至23%(p<.0001),第二次ASCT组从34%升至55%(p=.02)。

核心结论

  • 帕比司他/GemBuMel方案对复发/难治或高危骨髓瘤患者有效,无进展生存优于接受美法仑或BuMel方案的同期匹配对照。

研究设计与样本

  • 前瞻性研究,入组80例18-65岁复发/难治或高危骨髓瘤患者,分为首次ASCT组(48例)和第二次ASCT组(32例)。
  • 与同期符合入组标准但接受美法仑或BuMel方案(非研究方案)的371例ASCT患者按年龄、既往治疗线数、高危细胞遗传学和ASCT时疗效进行匹配比较。
  • 治疗方案:帕比司他20 mg/天(第-9至-2天)联合吉西他滨/白消安/美法仑(第-8至-2天)。

主要发现

  • 首次ASCT组和第二次ASCT组中,高危细胞遗传学分别为33例和15例;对治疗无反应者分别为12例和11例;中位既往治疗线数分别为2线和3线。
  • 移植相关死亡2例,均发生在第二次ASCT组。
  • 1年无进展生存率:首次ASCT组69%,第二次ASCT组72%;1年总生存率:首次ASCT组79%,第二次ASCT组84%。
  • 微小残留病阴性率:首次ASCT组从8.5%升至23%(p<.0001),第二次ASCT组从34%升至55%(p=.02),且与结局改善相关。
  • 试验组与对照组(N=371)的移植相关死亡和ASCT后维持治疗相似;试验组首次ASCT(p=.02)或第二次ASCT(p=.04)后无进展生存均优于匹配对照。

临床怎么用

  • 作者认为帕比司他/GemBuMel方案对复发/难治或高危骨髓瘤患者有效,可作为首次或第二次ASCT的选项。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Improvement of autologous stem-cell transplantation (ASCT) for myeloma is needed. Building on our prior work, we prospectively evaluated panobinostat and gemcitabine/busulfan/melphalan (GemBuMel) with ASCT in this population. Patients aged 18-65 years with relapsed/refractory or high-risk myeloma and adequate end-organ function were eligible. Treatment included panobinostat (20 mg/day, days -9 to -2) and GemBuMel (days -8 to -2). Patients were enrolled in 1st (ASCT-1) or 2nd ASCT (ASCT-2) cohorts. We compared their outcomes with all our other concurrent ASCT patients who met eligibility criteria but received melphalan or BuMel off study, matched for age, prior therapy lines, high-risk cytogenetics, and response at ASCT. We enrolled 80 patients, 48 and 32 in the ASCT-1 and ASCT-2 cohorts, respectively; in these two cohorts, high-risk cytogenetics were noted in 33 and 15 patients, respectively; unresponsive disease in 12 and 11 patients, respectively, after a median of 2 and 3 therapy lines, respectively. Transplant-related mortality (TRM) occurred in two ASCT-2 patients. One-year PFS rates were 69% (ASCT-1) and 72% (ASCT-2); 1-year OS rates were 79% (ASCT-1) and 84% (ASCT-2). Minimal residual disease negativity improved after ASCT-1 (8.5%-23%, p < .0001) and ASCT-2 (34%-55%, p = .02), which correlated with improved outcomes. Trial patients and controls (N = 371) had similar TRM and post-ASCT maintenance. Trial patients had better PFS after either a 1st (p = .02) or a 2nd ASCT (p = .04) than matched-paired control patients. In conclusion, panobinostat/GemBuMel is effective for relapsed/refractory or high-risk myeloma patients, with better PFS than concurrent matched controls receiving melphalan or BuMel.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Nieto Y, Yang Z, Valdez BC, et al. Safety and efficacy of a new high-dose regimen of panobinostat, gemcitabine, busulfan, and melphalan for 1st or 2nd salvage ASCT for refractory/relapsed or high-risk myeloma: Matched-pair comparisons with concurrent control cohorts. Am J Hematol. 2023. PMID: 38100199. doi:10.1002/ajh.27168

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。